Most-Upgraded StocksMost-UpgradedNASDAQ:AMGN Amgen (AMGN) Stock Price, News & Analysis $435.52 -3.30 (-0.75%) Closing price 11/20/2026 03:59 PM EasternExtended Trading$438.02 +2.51 (+0.58%) As of 11/20/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Amgen Stock (NASDAQ:AMGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Amgen alerts:Sign Up Key Stats Today's Range$434.51▼$445.4950-Day Range$375.65▼$478.4852-Week Range$312.39▼$483.99Volume4.94 million shsAverage Volume2.66 million shsMarket Capitalization$235.58 billionP/E Ratio19.94Dividend Yield2.31%Price Target$428.62Consensus RatingHold Company Overview Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.AI Generated. May Contain Errors. Read More Amgen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks84th Percentile Overall ScoreAMGN MarketRank™: 4.188794661475 of 5 starsAmgen scored higher than 84% of companies evaluated by MarketBeat, and ranked 59th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.2 / 5Analyst RatingHold Consensus RatingAmgen has received a consensus rating of Hold. The company's average rating score is 2.30, and is based on 1 strong buy rating, 11 buy ratings, 18 hold ratings, and 3 sell ratings.Upside/DownsideThe consensus price target for Amgen is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageAmgen has been the subject of 25 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Amgen's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth7.01% Earnings GrowthEarnings for Amgen are expected to grow by 7.01% in the coming year, from $23.41 to $25.05 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amgen is 19.94, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.24.Price to Earnings Ratio vs. SectorThe P/E ratio of Amgen is 19.94, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.06.Price to Earnings Growth RatioAmgen has a PEG Ratio of 3.22. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAmgen has a P/B Ratio of 16.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Amgen's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.35% of the float of Amgen has been sold short.Short Interest Ratio / Days to CoverAmgen has a short interest ratio ("days to cover") of 4.97.Change versus previous monthShort interest in Amgen has recently decreased by 5.87%, indicating that investor sentiment is improving significantly. Dividend4.2 / 5Dividend StrengthStrong Dividend YieldAmgen pays a meaningful dividend of 2.18%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthAmgen has been increasing its dividend for 14 years.Dividend CoverageThe dividend payout ratio of Amgen is 58.47%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Amgen will have a dividend payout ratio of 40.24% next year. This indicates that Amgen will be able to sustain or increase its dividend.Read more about Amgen's dividend. News and Social Media4.2 / 5News Sentiment0.74 News SentimentAmgen has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 24 news articles for Amgen this week, compared to 9 articles on an average week.Search Interest42 people have searched for AMGN on MarketBeat in the last 30 days. This is an increase of 35% compared to the previous 30 days.MarketBeat Follows23 people have added Amgen to their MarketBeat watchlist in the last 30 days. This is an increase of 156% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Amgen insiders have not sold or bought any company stock.Percentage Held by Insiders0.85% of the stock of Amgen is held by insiders.Percentage Held by Institutions76.50% of the stock of Amgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amgen's insider trading history. Receive AMGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AMGN Stock News HeadlinesAmgen (NASDAQ:AMGN) Stock Rating Reaffirmed as "Overweight" by Piper Sandler1 hour ago | americanbankingnews.comJim Cramer Rejects UiPath Despite Cheap Valuation, Backs AffirmNovember 20 at 8:11 AM | benzinga.comSeven bucks, yours for life: my Black Friday indicator dealBase Camp Trading's Thomas Wood is giving away his proprietary Snapback Indicator for just $7 this Black Friday. Others paid $500 for it. It's a one-time price with no recurring billing, and the indicator is yours for life. It shows when it's time to sell or go short, and when it makes sense to buy. Check it for a potential Snapback before your next trade. | Base Camp Trading (Ad)Amgen (AMGN) Stock Price Target 2026November 19 at 8:01 PM | benzinga.comViridian Therapeutics' Lumvoa Emerging as Rival to Amgen's Tepezza, BofA Securities SaysNovember 19 at 3:00 PM | finance.yahoo.comAmgen (AMGN) Has Advanced MariTide Into Phase 3 TrialsNovember 19 at 9:59 AM | finance.yahoo.comAmgen (NASDAQ:AMGN) Stock Price Expected to Rise, Barclays Analyst SaysNovember 18 at 1:18 AM | americanbankingnews.comBiotechnology Market Companies 2027 Analysis: Amgen, Gilead, Regeneron, Vertex and Moderna Post Strong 2026 Results as Billion-Dollar Deals Reshape a Market Headed for USD 6.34 Trillion by 2035November 17, 2026 | finance.yahoo.comSee More Headlines AMGN Stock Analysis - Frequently Asked Questions How have AMGN shares performed this year? Amgen's stock was trading at $327.31 at the beginning of the year. Since then, AMGN stock has increased by 33.1% and is now trading at $435.5170. How were Amgen's earnings last quarter? Amgen Inc. (NASDAQ:AMGN) released its quarterly earnings results on Tuesday, November, 3rd. The medical research company reported $6.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.79 by $0.66. Amgen's revenue was up 8.5% on a year-over-year basis. Read the conference call transcript. Does Amgen have any subsidiaries? The following companies are subsidiaries of Amgen: TeneoBio, Five Prime Therapeutics, Rodeo Therapeutics, Otezla, Nuevolution, Catherex, Catherex, and more. Who are Amgen's major shareholders? Amgen's top institutional investors include State Street Corp (5.72%), Fisher Asset Management LLC (0.31%), Assenagon Asset Management S.A. (0.28%) and Sumitomo Mitsui Trust Group Inc. (0.27%). Insiders that own company stock include Murdo Gordon, David M Reese, Jonathan P Graham, Nancy A Grygiel, Nancy A Grygiel and Rachna Khosla. View institutional ownership trends. How do I buy shares of Amgen? Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amgen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amgen investors own include NVIDIA (NVDA), Johnson & Johnson (JNJ), AbbVie (ABBV), Pfizer (PFE), Bristol Myers Squibb (BMY), JPMorgan Chase & Co. (JPM) and Intel (INTC). Company Calendar Record date for 9/11 Dividend8/21/2026Ex-Dividend for 9/11 Dividend8/21/2026Dividend Payable9/11/2026Last Earnings11/03/2026Today11/20/2026Record date for 12/11 Dividend11/20/2026Ex-Dividend for 12/11 Dividend11/20/2026Dividend Payable12/11/2026Fiscal Year End12/31/2026Next Earnings (Estimated)2/02/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 AMGN's financial health is in the Green zone, according to TradeSmith. AMGN has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:AMGN CIK318154 Webwww.amgen.com Phone(805) 447-1000Fax805-447-1010Employees31,500Year Founded1980Price Target and Rating Average Price Target for Amgen$428.62 High Price Target$542.00 Low Price Target$200.00 Potential Upside/Downside-1.6%Consensus RatingHold Rating Score (0-4)2.30 Research Coverage33 Analysts Profitability EPS (Trailing Twelve Months)$17.24 Trailing P/E Ratio19.94 Forward P/E Ratio17.39 P/E Growth3.22Net Income$7.71 billion Net Margins24.14% Pretax Margin28.41% Return on Equity114.99% Return on Assets13.47% Debt Debt-to-Equity Ratio3.60 Current Ratio1.48 Quick Ratio1.20 Sales & Book Value Annual Sales$36.75 billion Price / Sales6.41 Cash Flow$31.84 per share Price / Cash Flow13.68 Book Value$26.53 per share Price / Book16.42Miscellaneous Outstanding Shares540,910,000Free Float536,313,000Market Cap$235.58 billion OptionableOptionable Beta0.43 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:AMGN) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amgen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amgen With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.